“Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials”, J of Skin, vol. 6, no. 6, p. s49, Nov. 2022, doi: 10.25251/skin.6.supp.49.